F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
University Hospital Heidelberg · Heidelberg University · +3 more institutions
Abstract
The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer 68Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, 68Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of 18F-labelled analogs. 18F-PSMA-1007 was selected among several 18F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake and fast, non-urinary background clearance. Here, we describe the properties of 18F-PSMA-1007 in human volunteers and patients. Radiation dosimetry of 18F-PSMA-1007 was determined in three healthy volunteers who underwent whole-body…
Citation impact
- FWCI
- 38.04
- Percentile
- 100%
- References
- 35
Authors
17- FLFrederik L. GieselCorresponding
University Hospital Heidelberg, Heidelberg University
- BHBoris Hadaschik
University Hospital Heidelberg, Heidelberg University
- JCJens Cardinale
German Cancer Research Center, Heidelberg University
- JPJan Philipp Radtke
University Hospital Heidelberg, Heidelberg University
- MVMaria Vinsensia
Heidelberg University, University Hospital Heidelberg
Topics & keywords
- Prostate cancer
- Medicine
- Biodistribution
- Glutamate carboxypeptidase II
- Nuclear medicine
- Positron emission tomography
- Lymph node
- Dosimetry
- Good health and well-being